Enlivex Therapeutics (ENLV), which is listed on the Nasdaq and the Tel Aviv Stock Exchange, continues to trade without any interruption. Due to a technical error, TipRanks mistakenly reported that the company, which develops a drug pipeline for the treatment of autoimmune and inflammatory conditions, had suspended trading. TipRanks unequivocally retracts that erroneous report.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Enlivex stock rose by .96% in Friday’s trading, and has traded sideways for the past three months. The company met earnings estimates in its past two reports.
